Debbie Rigby rounds up the latest in research news
A systematic review of 67 RCTs concluded that there is moderate certainty of evidence that anticonvulsant medications and SNRIs provide a clinically meaningful reduction in pain in those with neuropathic pain. There is also some evidence for rubefacients and opioids, and very low certainty of evidence for TCAs. Anticonvulsant medications and SNRIs have a NNT of 7, and opioids NNT is 8. All drug classes, except TCAs, had a greater likelihood of deriving a clinically meaningful benefit than having withdrawals due to adverse events (number needed to harm between 12 and 15).
Canadian Family Physician May 2021, 67 (5) e130-e140.
A linked systematic review and network meta-analysis (764 randomised trials included 421 346 participants) of benefits and harms found that SGLT-2 inhibitors and GLP-1 receptor agonists generally reduce overall death, and incidence of myocardial infarctions, and end-stage kidney disease or kidney failure. Absolute effects of benefit varied widely based on patients’ individual risk.
This article provides an overview of pharmacotherapy management of schizophrenia through a case-based approach. Appropriate use of antipsychotic medications is the cornerstone of the management of schizophrenia. Adherence to treatment is imperative in reducing the risk of psychotic relapse. Adverse drug effects should be monitored for continuously, with more rigorous monitoring at times of antipsychotic initiation or dose changes.
Canadian Family Physician May 2021, 67 (5) 350-354.
This position statement considers the evolving evidence on the use of coronary artery calcium scoring (CAC) for defining cardiovascular risk in the context of Australian practice and provides advice to health professionals regarding the use of CAC scoring in primary prevention of cardiovascular disease in Australia.
MJA, first published 7 May 2021.